---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-096235"
form_type: "8-K"
ticker: "PLYX"
cik: "0002075320"
company_name: "Polaryx Therapeutics, Inc."
filed_at: "2026-09-01T20:30:15+00:00"
generated_at: "2026-09-01T20:31:32.371386+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Polaryx appoints Dr. Will Charlton as Chief Medical Officer; SOTERIA Phase 2 on track for Q4 2026

## Summary
- Dr. Charlton appointed CMO effective Sept 1, 2026; brings 15+ years rare disease/pediatric drug development experience.
- Previously SVP Clinical Development at Tyra Biosciences; led Phase 2 rare disease trial; also CMO at Spruce Biosciences.
- SOTERIA Phase 2 trial of PLX-200 in CLN2, CLN3, Krabbe, Sandhoff diseases; FDA safe-to-proceed Oct 2025; initiation planned Q4 2026.
- Dr. Charlton's background includes roles at 89bio, Ascendis Pharma, Allergan; board-certified pediatric endocrinologist.

## SEC filing metadata
- accession: 0001213900-26-096235
- form_type: 8-K
- ticker: PLYX
- cik: 0002075320
- company_name: Polaryx Therapeutics, Inc.
- filed_at: 2026-09-01T20:30:15+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/0001213900-26-096235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/ea0303928-8k_polaryx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-096235
- JSON: https://secwatch.observer/filing/0001213900-26-096235.json
- Plain text: https://secwatch.observer/filing/0001213900-26-096235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.